stockportfolio.pro
Stocks / ALKS vs IBRX
ALKS vs IBRX
Alkermes plc and ImmunityBio, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Alkermes plc (ALKS) | ImmunityBio, Inc. (IBRX) | |
|---|---|---|
| Market cap | $7.3B | $7.5B |
| Revenue (latest FY) | $1.48B | $113.29M |
| Net income (latest FY) | $241.66M | $-351.40M |
| Revenue growth (5y CAGR) | 7.3% | 184.8% |
| Net margin | 16.4% | -310.2% |
| Return on equity | 13.3% | 70.2% |
| P/E ratio | 49.0 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ALKS — free Open IBRX — freeFrequently asked questions
Which is bigger, ALKS or IBRX?
ImmunityBio, Inc. is larger by market capitalization — $7.5B versus $7.3B.
Which grows faster, ALKS or IBRX?
Over the last five fiscal years, ImmunityBio, Inc. grew revenue faster — 184.8%/yr versus 7.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.